Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AstraZeneca Scores Lung Cancer Touchdown, While Clovis Fumbles

This article was originally published in The Pink Sheet Daily

Executive Summary

Both AstraZeneca’s Tagrisso and Clovis’ rociletinib target metastatic EGFR T790M mutation-positive non-small cell lung cancer. Tagrisso was approved by FDA Nov. 13, while Clovis said its drug would be delayed because mature data showed fewer confirmed responses than earlier data.

Advertisement

Related Content

Boehringer’s Oncology Strategy: Build From Niche Lung Cancer Base
AstraZeneca’s Iressa, Now Resurrected, Faces Daunting U.S. EGFR Market
AstraZeneca Staking Its Growth On Oncology; Now It Needs Cancer Drugs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077993

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel